BioNTech SE (VIE:BNTX)

Market Cap	22.99B -11.8%
Revenue (ttm)	3.15B +3.7%
Net Income	-571.60M
EPS	-2.38
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90
Average Volume	511
Open	93.45
Previous Close	93.30
Day's Range	93.05 - 93.45
52-Week Range	72.40 - 118.40
Beta	n/a
RSI	49.23
Earnings Date	Mar 10, 2026

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 6,772
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: BNTX